ATM kinase inhibitors and compositions and methods of use thereof

A compound of Formula I:

• or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof;
• wherein:
• ring B is a heterocycloalkyl ring optionally having 1 to 3 additional heteroatoms selected from O, N, and S;
• X is CH or N;
• (i) Z is N and Y is —CH(R1)— or —CH2—;
• or
• (ii) Z—Y is —C═C(R1)— or —C═C(H)—;
• L is C1-3 alkylene optionally substituted with C1-4alkoxy;
• each R1 is independently C1-4alkyl, halo-C1-4alkyl, C1-4alkoxy, halo-C1-4alkoxy, or C3-6 cycloalkyl;
• or two R1, together with the carbon atoms to which they are attached, join to form a cycloalkyl ring;
• each R2 is independently selected from hydroxy, halo, C1-4alkyl optionally substituted with C1-4alkoxy, halo-C1-4alkyl optionally substituted with C1-4alkoxy, C1-4alkoxy optionally substituted with cycloalkyl, halo-C1-4alkoxy, C3-6 cycloalkyl, and C3-6 cycloalkoxy;
• or two R2, when present on the same carbon atom, join to form oxo;
• or two R2, together with the carbon atoms to which they are attached, join to form a C3-7 cycloalkyl ring optionally substituted with 1 to 3 halo or a 3- to 7-membered heterocycloalkyl ring optionally substituted with 1 to 3 halo, wherein the heterocycloalkyl ring contains 1 to 3 heteroatoms selected from N, O, and S;
• R3 is H or C1-6alkyl optionally substituted with —N(R8)(R9), C1-4alkoxy, or C3-6 cycloalkyl;
• R4 is H or halo;
• R5 is an aryl or 5- to 10-membered heteroaryl having 1, 2, 3, or 4 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1 to 3 R6;
• each R6 is independently halo, C1-6alkyl, halo-C1-6alkyl, or —OR7;
• each R7 is independently selected from heterocycloalkyl and C1-6alkyl optionally substituted with C1-4alkoxy or halo;
• R8 and R9 are each independently selected from H and C1-6alkyl;
• p is 0, 1, 2, or 3;
• and
• m is 0, 1, 2, or 3.